STAT3 and central nervous system cancer: In the control-treated NSC11 gliomas, the mean percentage of p-STAT3 expressing tumor cells was 9.0 + 4.4% (median 6.4; range: 5.1 – 14.0; n=5), whereas in the bevacizumab-treated cohort, the mean was 24.6 + 6.4% (median 22.7; range: 16.0 – 33.3; n=6; P=0.008 by pair comparison).